PEPTIDE GUARDIANResearch literacy for peptides

Guides

Neuro and cognitive: what the research shows

Compounds studied for sleep, anxiety and brain function. This guide covers 3 of them. For each one: what is established in people, the key studies, and its status.

From our publisherAMINOSWORK, the research peptide supplier behind Peptide Guardian, posts its third-party lab reports by lot number. Open the lab report library

DSIP

Early human trials

DSIP is a nine-amino-acid peptide first isolated from rabbit blood in 1977; a handful of small trials in the 1980s and early 1990s gave mixed results for sleep, and no approved medicine followed.

Very little is established in people. The human studies date from 1981 to 1992, plus one in 2009, and all gave DSIP into a vein. The early positive insomnia reports had no placebo group. The two properly controlled insomnia trials, in 6 and 16 people, found weak or no benefit. The largest study, 107 patients in withdrawal, had no comparison group. No trial has tested the injection under the skin that is sold today.

Key studies

  • Human trial, 2009. DSIP raised heart rate, reduced delta brain-wave activity and lightened the measured depth of anaesthesia. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 1994. Natural DSIP-like material in the blood was lower during deep sleep and dream sleep than when awake. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 1992. Sleep efficiency was a little higher and sleep onset a little quicker with DSIP, but the authors called the effects weak and said they could partly be due to a chance change in the placebo group. Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not approved. FDA proposed not allowing compounding. Not in the October 2026 federal draft policy.
In sport
Not named; unapproved, so it falls under class S0, prohibited at all times.

All 12 studies on the DSIP page

Selank

Early human trials

Selank is a seven-amino-acid synthetic peptide made in Moscow from the immune peptide tuftsin; its human evidence is a few small Russian studies in anxiety with no placebo group, and it is not approved in the United States.

Very little is established in people. The patient studies found were three small Russian comparisons in anxiety disorders (62, 60 and 70 patients) against or alongside benzodiazepine tranquillisers, with no placebo group, and their abstracts do not describe randomisation, blinding or detailed side effects. They come from one research network linked to the developers and were published in Russian. A 2020 brain-scan study in 52 healthy volunteers measured scan patterns, not symptoms. No trial is registered on ClinicalTrials.gov and no independent trial outside Russia was found.

Key studies

  • Human trial, 2020. The groups differed in how strongly the right amygdala (a brain area involved in fear and anxiety) was connected with parts of the right temporal lobe. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2015. Adding selank was reported to make phenazepam work sooner on a depression rating scale (HDRS), to reduce several of phenazepam's side effects during treatment and after it was stopped (including memory and attention problems, sedation, tiredness, sexual problems and dizziness on standing), and to improve quality of life. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2014. The authors reported a clear anti-anxiety effect and a mild effect on thinking and memory, with better quality of life. Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not FDA-approved. Nomination for compounding withdrawn; not in the October 2026 federal draft policy.
In sport
Not named. S0 status unclear because of its reported Russian registration.

All 12 studies on the Selank page

Semax

Early human trials

Semax is a seven-amino-acid peptide built from a fragment of the hormone ACTH and registered as a nasal medicine in Russia; its human evidence comes from small, mostly uncontrolled Russian studies, and the FDA judged it insufficient.

Very little is established in people by international standards. The human studies of stroke, reduced brain blood flow, optic nerve disease and motor neuron disease come from Russia, are small, are mostly in Russian-language journals, and often had no placebo group or did not describe how patients were assigned; many came from groups linked to semax's development. The FDA excluded the Russian stroke studies for lack of English translations, and judged the two studies it could assess too weak to show benefit. No independent trials outside Russia and no trials on ClinicalTrials.gov were found. The one study in motor neuron disease found no effect on the disease.

Key studies

  • Human trial, 2018. Patients given semax had higher BDNF in the blood throughout the study, whatever the timing of rehabilitation. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2018. Brain scans at rest (functional MRI) showed changes in a network of brain areas active during rest in the semax group compared with the placebo group. Source: pubmed.ncbi.nlm.nih.gov
  • Human trial, 2007. Semax did not change the course of nerve damage measured by muscle tests, or the clinical rating scales of the disease. Source: pubmed.ncbi.nlm.nih.gov
FDA status
Not FDA-approved; registered in Russia. FDA staff opposed compounding; an October 2026 HHS draft policy covers nasal use.
In sport
Not named on the List; status unsettled since it is a registered medicine in Russia.

All 15 studies on the Semax page

Before you trust any seller

A study tells you about the compound. It tells you nothing about what is in a particular vial. How to read a lab report

Sources last checked 2026-11-18.

This page summarises published research and public records for education. It is not medical advice and it is not a guide to using any compound. If something here is wrong or out of date, tell us and we will correct it.

Get the Guardian Field Guide

Every compound on this site in one guide: what it is, what studies found, and where it stands with regulators. Sign up and it opens right away.